Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Alzheimer, ASU, contemporaneously, EANM, fifty, formula, Gothenburg, LP, Multiple, necessity, PPD, prepaid, promptly, quantity, SubsidiaryCONSOLIDATED, Sweden
Removed:
achievement, agreeing, angina, arterial, atherosclerotic, attracting, cerebral, chest, clot, constantly, conventional, correlate, David, decreased, default, desirable, devoting, diadenosine, diagnosed, differentiate, differentiated, Elmaleh, enrolled, entry, factor, formation, FPM, grow, image, infiltration, inflamed, inflammation, inflammatory, Intent, ischemia, leased, line, LOI, lumen, narrow, narrowing, objective, overlying, pain, progressively, rest, royalty, rupture, schedule, Skriloff, stipulate, straight, supplier, thought, thrombi, unaddressed, undergone, unqualified
Filing tables
Filing exhibits
- 10-K Annual report
- 10.13 Second Amendment to Lease Agreement Between Hilsside Square, LLC and Fluoropharma Medical, Inc. Dated As of February 2015
- 23.1 Consent of Wolf & Company, P.C.
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14 of the Securities Exchange Act of 1934.
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14 of the Securities Exchange Act of 1934.
- 32.1 Certification of Chief Executive Officer Pursuant to Section 1350.
- 32.2 Certification of Chief Financial Officer Pursuant to Section 1350.
- Download Excel data file
- View Excel data file
FPMI similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement (No. 333-185648) on Form S-8 of FluoroPharma Medical, Inc. of our report dated March 31, 2015, relating to our audit of the consolidated financial statements, which appear in this Annual Report on Form 10-K of FluoroPharma Medical, Inc. for the years ended December 31, 2014 and 2013. Our report dated March 31, 2015, relating to the consolidated financial statements includes an emphasis paragraph relating to an uncertainty as to the Company's ability to continue as a going concern.
/s/ Wolf & Company, P.C.
Boston, Massachusetts
March 31, 2015